Summary & Overview
CPT 90660: Trivalent Live Influenza Vaccine, Intranasal
CPT code 90660 denotes a trivalent live attenuated influenza vaccine administered intranasally. As a non-injectable influenza immunization option, this code is used for seasonal vaccination programs and ambulatory immunization services. The nasal spray formulation is clinically important as an alternative for certain age groups and patients for whom intranasal delivery is appropriate.
Key payers examined in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Coverage and coding practices for 90660 affect vaccination program implementation, billing workflows, and payer-provider communication during flu seasons.
Readers will find a national overview of the code's clinical context, typical sites of service, and operational considerations for ambulatory immunization delivery. The publication also covers payer coverage patterns, common billing modifiers associated with vaccination services, and practical benchmarking where available. Policy updates relevant to vaccine coding and reimbursement are summarized, along with guidance on documentation elements typically associated with vaccine administration claims. Data not available in the input will be identified as such.
Billing Code Overview
CPT code 90660 represents a trivalent live influenza vaccine delivered as a nasal spray. The product contains three different influenza virus strains and is intended to provide immunization against seasonal influenza.
-
Service type: Vaccine administration (nasal, live attenuated trivalent influenza vaccine)
-
Typical site of service: Outpatient clinic, primary care office, public health clinic, school-based clinic, pharmacy clinic, or other ambulatory care settings where intranasal vaccinations are provided.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a healthy pediatric or young adult presenting to an outpatient clinic or community vaccination site during influenza season for routine immunization. The provider confirms eligibility (age and absence of contraindications such as severe egg allergy or immunocompromise), reviews recent respiratory symptoms and recent live vaccines, obtains verbal consent, documents current medications and pregnancy status for females of childbearing potential, and administers the trivalent live attenuated intranasal influenza vaccine 90660 as a single-dose nasal spray. Post-administration observation for 15–30 minutes is performed to monitor for immediate adverse reactions. Documentation includes vaccine lot number, expiration date, administration site (intranasal), manufacturer, informed consent, and counseling provided. Typical sites of service are outpatient clinic, physician office, public health clinic, school-based clinic, and pharmacy-based immunization sites where permitted by state law.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unmodified procedure | Use when no modifier applies and service is performed as billed |
25 |